Isadora Mella Muñoz¹, Micaela Osorio Cane¹, Manuel Alvarez Vaccaro² and Alejandro Alvarez Jara³*

¹Medical Intern, Faculty of Medicine, University of Concepción, Chile
²Medical Student, Faculty of Medicine, University of Development, Santiago, Chile
³Pediatrician-Pediatric and Fetal Cardiologist, Fetal Exploration Unit, Guillermo
Grant Benavente Hospital, Concepción, Chile

*Corresponding Author: Alejandro Alvarez Jara, Pediatrician-Pediatric and Fetal Cardiologist, Fetal Exploration Unit, Guillermo Grant Benavente Hospital, Concepción, Chile.

Received: March 30, 2026; Published: May 08, 2026

Abstract

Rhabdomyomas are the most common fetal cardiac tumor and are generally associated with tuberous sclerosis, a disease in which tumor suppressor genes mutate, leading to abnormal cell proliferation. They can cause a variety of manifestations, with larger tumors potentially causing hemodynamic instability due to outflow tract obstruction, requiring surgical intervention. Therefore, sirolimus has emerged as a conservative management option. This drug is an mTOR inhibitor of rapamycin, which possesses antitumor activity. We present three cases of fetal cardiac rhabdomyomas with different characteristics. Two were treated with sirolimus, resulting in complete regression without adverse effects or the need for surgical intervention. The third patient, with small rhabdomyomas and no hemodynamic compromise, was followed up in an outpatient clinic with excellent progress.

Keywords: Fetal Rhabdomyoma; Cardiac Rhabdomyoma; Prenatal Diagnosis and Tratamiento

References

1. Rathore B., et al. “Fetal cardiac masses”. Pediatric Radiology11 (2025): 2400-2416.
2. Mustafa HJ., et al. “Characteristics and Outcomes of Fetal Cardiac Rhabdomyoma With or Without mTOR Inhibitors, a Systematic Review and Meta-Analysis”. Prenatal Diagnosis10 (2024): 1251-1267.
3. Vander Salm TJ., et al. “Cardiac tumors”. UpToDate (2024).
4. Ng LY., et al. “Cardiac Rhabdomyomas Presenting with Critical Cardiac Obstruction in Neonates and Infants: Treatment Strategies and Outcome, A Single-Center Experience”. Pediatric Cardiology5 (2024): 1132-1141.
5. Randle S., et al. "Tuberous sclerosis complex: Clinical features". UpToDate (2025).
6. Hardinger K., et al. “Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors”. UpToDate (2025).
7. Randle S., et al. "Tuberous sclerosis complex: Clinical features”. UpToDate (2025).
8. Muschel N., et al. “Drug review: mTOR-inhibitor therapy in fetal cardiac rhabdomyoma-a tightrope walk”. Frontiers in Pediatrics 13 (2025): 1649341.
9. Park H., et al. “Sirolimus therapy for fetal cardiac rhabdomyoma in a pregnant woman with tuberous sclerosis”. Obstetrics and Gynecology Science4 (2019): 280-284.
10. Ebrahimi-Fakhari D., et al. “Prenatal sirolimus treatment for rhabdomyomas in tuberous sclerosis”. Pediatric Neurology 125 (2021): 26-31.

Citation

Citation: Alejandro Alvarez Jara., et al. “Fetal Rhabdomioma: Report of Three Cases". Acta Scientific Nutritional Health 10.5 (2026): 12-15

Copyright

Copyright: © 2026 lejandro Alvarez Jara., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.